Astrana Health Q2 Revenue Misses, But EPS Crushes Estimates and Guidance Raised
ASTH sits 86% above its 52-week low of $18.08.
Summary
Astrana Health reported Q2 revenue of $972.5M, up 49% YoY but below consensus, while adjusted EPS of $0.80 demolished the $0.34 estimate. The company raised its full-year adjusted EBITDA guidance to $255M-$280M, citing accelerating platform demand and value-based care expansion. This follows the 8-K filed today with the same figures, but adds analyst reaction and forward guidance details. The revenue miss is overshadowed by the massive earnings beat and raised outlook, signaling strong operational leverage. Q3 guidance calls for $1.0B-$1.03B in revenue and $72.5M-$77.5M in adjusted EBITDA.
Updates
· SEC 10-Q — The 10-Q reports net income attributable to Astrana of $19.7M for Q2 and $34.2M for H1 2026, with total assets of $2.28B and long-term debt of $882.7M as of June 30, 2026.
At the time of this announcement, ASTH was trading at $33.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $18.08 to $51.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.